ProCE Banner Activity

The Future: Opportunities for Predictive Biomarkers for Cancer Immunotherapy

Slideset Download
Download this slideset to gain expert insights on promising new biomarkers predicting response to checkpoint inhibitors in lung cancer, including thoughts on TMB, MSI, and immunogenic neoantigen burden.

Released: November 05, 2019

Expiration: November 03, 2020

No longer available for credit.

Share

Faculty

Hossein Borghaei

Hossein Borghaei, MS, DO

Associate Professor
Chief,
Thoracic Medical Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Sandip P. Patel

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Program Director Disclosure

Program Director

Hossein Borghaei, MS, DO

Associate Professor
Chief,
Thoracic Medical Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Faculty Disclosure

Primary Author

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California